Search research articles
Contact Us
Filters
Showing results (71-80 of 126) with videos related to
Page
of 13
Sort By:
British Journal of Clinical Pharmacology
|
April 14, 2019
Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients
Cong Zhou, Sarah Taylor, Jonathan Tugwood, et al.
Journal of Clinical Gastroenterology
|
October 25, 2013
Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer
Leila Khoja, Gireesh Kumaran, Ying Kiat Zee, et al.
The Journal of Biological Chemistry
|
August 29, 2012
Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor
Cristina Ferreras, Graham Rushton, Claire L Cole, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2014
The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer
Alison Backen, Andrew G Renehan, Andrew R Clamp, et al.
Magnetic Resonance in Medicine
|
October 31, 2007
Tracer kinetic model-driven registration for dynamic contrast-enhanced MRI time-series data
Giovanni A Buonaccorsi, James P B O'Connor, Angela Caunce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 7, 2004
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
E June Davies, Fiona H Blackhall, Jonathan H Shanks, et al.
British Journal of Cancer
|
June 29, 2016
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
Cong Zhou, Andrew Clamp, Alison Backen, et al.
Journal for Immunotherapy of Cancer
|
December 11, 2021
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
Victor Moreno, Maria-Pilar Barretina-Ginesta, Jesús García-Donas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2005
Heparin octasaccharides inhibit angiogenesis in vivo
Jurjees Hasan, Steven D Shnyder, Andrew R Clamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma
James P B O'Connor, Gordon C Jayson, Alan Jackson, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 126) with videos related to
Sort By:
Page
of 13
British Journal of Clinical Pharmacology
|
April 14, 2019
Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients
Cong Zhou, Sarah Taylor, Jonathan Tugwood, et al.
Journal of Clinical Gastroenterology
|
October 25, 2013
Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer
Leila Khoja, Gireesh Kumaran, Ying Kiat Zee, et al.
The Journal of Biological Chemistry
|
August 29, 2012
Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor
Cristina Ferreras, Graham Rushton, Claire L Cole, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2014
The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer
Alison Backen, Andrew G Renehan, Andrew R Clamp, et al.
Magnetic Resonance in Medicine
|
October 31, 2007
Tracer kinetic model-driven registration for dynamic contrast-enhanced MRI time-series data
Giovanni A Buonaccorsi, James P B O'Connor, Angela Caunce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 7, 2004
Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer
E June Davies, Fiona H Blackhall, Jonathan H Shanks, et al.
British Journal of Cancer
|
June 29, 2016
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
Cong Zhou, Andrew Clamp, Alison Backen, et al.
Journal for Immunotherapy of Cancer
|
December 11, 2021
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial
Victor Moreno, Maria-Pilar Barretina-Ginesta, Jesús García-Donas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2005
Heparin octasaccharides inhibit angiogenesis in vivo
Jurjees Hasan, Steven D Shnyder, Andrew R Clamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2007
Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma
James P B O'Connor, Gordon C Jayson, Alan Jackson, et al.
Page
of 13